Sign up to get updates from us
The only people that like infusion suites are those who own them. Payers don’t like them. Patients hate them. But for many drugs, due to their molecular nature there is simply no choice, and this has been the case with the class of drugs known as checkpoint inhibitors—until now. Now there is Envafolimab, a novel anti-PD-L1 antibody from Tracon Pharma with a low volume, subcutaneous administration that is already being tested in the clinic in multiple indications. Listen in as CEO Charles Theuer describes his licensing strategy that brought Envafolimab, as well assets targeting CTLA-4, CD73, and DNA repair mechanisms on board.
